

1 **Lipidomic profiling of human serum enables detection of pancreatic cancer**

2 Denise Wolrab¹, Robert Jirásko¹, Eva Cífková¹, Marcus Höring², Ding Mei^{3,4}, Michaela
3 Chocholoušková¹, Ondřej Peterka¹, Jakub Idkowiak¹, Tereza Hrnčiarová¹, Ladislav Kuchař⁵,
4 Robert Ahrends⁶, Radana Brumarová⁷, David Friedecký⁷, Gabriel Vivo-Truyols⁸, Pavel
5 Škrha⁹, Jan Škrha¹⁰, Radek Kučera¹¹, Bohuslav Melichar¹², Gerhard Liebisch², Ralph
6 Burkhardt², Markus R. Wenk^{3,4}, Amaury Cazenave-Gassiot^{3,4}, Petr Karásek¹³, Ivo Novotný¹³,
7 Roman Hrstka¹⁴, Michal Holčapek^{1*}

8 ¹ Department of Analytical Chemistry, Faculty of Chemical Technology, University of
9 Pardubice, Pardubice, Czech Republic.

10 ² Institute of Clinical Chemistry and Laboratory Medicine, University Hospital of
11 Regensburg, Regensburg, Germany.

12 ³ Singapore Lipidomics Incubator (SLING), Life Sciences Institute, National University of
13 Singapore, Singapore.

14 ⁴ Department of Biochemistry, Yong Loo Lin School of Medicine, National University of
15 Singapore, Singapore.

16 ⁵ Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First
17 Faculty of Medicine, Charles University and General University Hospital in Prague, Prague,
18 Czech Republic.

19 ⁶ Department of Analytical Chemistry, University of Vienna, Vienna, Austria.

20 ⁷ Palacký University Olomouc, Institute of Molecular and Translational Medicine, Olomouc,
21 Czech Republic.

22 ⁸ Tecnometrix, Ciutadella De Menorca, Spain.

23 ⁹ Third Faculty of Medicine, Charles University, Prague, Czech Republic.

24 ¹⁰ 3rd Department of Internal Medicine, First Faculty of Medicine, Charles University, Czech
25 Republic.

26 ¹¹ Department of Immunochemistry Diagnostics, University Hospital in Pilsen, Pilsen, Czech
27 Republic.

28 ¹² Department of Oncology, Faculty of Medicine and Dentistry, Palacký University and
29 University Hospital, Olomouc, Czech Republic.

30 ¹³ Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech
31 Republic.


32 ¹⁴ Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute,
33 Brno, Czech Republic.

34 * Correspondence to: Michal.Holcapek@upce.cz

35 **Pancreatic cancer has the worst prognosis among all cancers¹. Cancer screening**
36 **programs based on the analysis of body fluids can improve the survival time of patients,**
37 **who are often diagnosed too late at an incurable stage². Several studies have reported**
38 **the dysregulation of lipid metabolism in tumor cells and tissues³, suggesting that the**
39 **changes of blood lipidome may accompany tumor growth and progression. Analytical**
40 **methods based on mass spectrometry (MS) using either direct infusion or**
41 **chromatographic separation⁴ are convenient for high-throughput lipidomic profiling.**
42 **Here we show that the comprehensive quantitation of a wide range of serum lipids**
43 **reveals statistically significant differences between pancreatic cancer patients and**
44 **healthy controls visualized by multivariate data analysis. Initial results for 364 human**
45 **serum samples in the discovery phase were subsequently verified in the qualification**
46 **phase on 554 samples measured by three independent laboratories, and finally on 830**
47 **samples from four blood collection sites in the verification phase. Concentrations**
48 **suggestive of dysregulation of some very long chain sphingomyelins (SM 42:1, SM 41:1,**
49 **SM 39:1, and SM 40:1), ceramides (Cer 41:1, and Cer 42:1), and**
50 **(lyso)phosphatidylcholines (LPC 18:2) were recorded. Some lipid species indicated a**
51 **potential as biomarkers of survival. The sensitivity and specificity to diagnose pancreatic**
52 **cancer is over 90%, which outperforms CA 19-9, especially in early stage, and is**
53 **comparable to established imaging diagnostic methods. The accuracy of lipidomic**
54 **approach is not influenced by the cancer stage, analytical method, or blood collection**
55 **site.**

56 Early cancer diagnosis based on non-invasive screening has been one of the major
57 unmet needs in medical research over the last decades¹. Some cancer types, such as pancreatic
58 cancer², do not show specific symptoms making the diagnosis at an early stage difficult.
59 Pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of pancreatic cancers, is
60 mostly diagnosed at late stage resulting in the worst 5-year survival rate (7%) among all
61 cancers⁵. Imaging modalities used to diagnose PDAC in clinical practice included magnetic
62 resonance imaging, computed tomography, endoscopic ultrasound, and positron emission
63 tomography, with accuracies reported in the meta-analysis of 5399 patients from 52 studies of
64 90%, 89%, 89%, and 84%, respectively⁶. Invasive procedures, *i.e.*, biopsies, were performed
65 only for the final confirmation of PDAC. Several types of blood tests were considered for
66 PDAC screening⁷⁻⁹, such as carbohydrate antigen (CA) 19-9 measured alone or with other
67 blood proteins, *e.g.*, carcinoembryonic antigen. The sensitivity and specificity of CA 19-9
68 were around 80% for advanced stages of PDAC, but dropped to 30-50% for small non-
69 metastatic tumors¹⁰, which prevents the utilization for early screening. *Kirsten-ras (KRAS)*
70 mutation testing currently used in the clinical practice for epithelial cancers (*e.g.*, lung or
71 colorectal cancers) was considered for PDAC diagnostic using liquid biopsies, but the
72 sensitivity was too low. This mutation encountered in more than 90% of PDAC¹¹ and was
73 related to inferior overall survival. *KRAS* may be involved in the metabolic reprogramming of
74 fast proliferating tumor cell population towards elevated glucose and glutamine flows defined
75 as one of the hallmarks of cancer¹². Furthermore, the uptake of nutrients in *KRAS* mutated
76 cells can include blood lipids for the cell proliferation and survival^{13,14}. *KRAS* mutation has
77 been reported to be associated with the lipid metabolism in pancreatic cancer cells¹⁵. Lipids
78 have numerous functions in human metabolism¹⁶. Changes in the lipid metabolism were
79 already reported in other cancer types³, mostly for cell lines¹⁷, tissues¹⁸, but less frequently for
80 body fluids¹⁹. MS based lipidomic analysis has proven to be robust for high-throughput

81 quantitation²⁰ and in combination with multivariate data analysis even small differences in
 82 lipid profiles can be detected³.



83

84 **Fig. 1. Overview of study design for the differentiation of PDAC patients (T, red) from**
 85 **normal healthy controls (N, blue) and pancreatitis patients (Pan, green) based on the**
 86 **lipidomic profiling of human serum using various mass spectrometry based approaches.**
 87 **a, Phase I (discovery) for 364 samples (262 T + 102 N) divided into training (213 T + 79 N)**
 88 **and validation (49 T + 23 N) sets measured by UHPSFC/MS, shotgun MS (LR), and MALDI-**
 89 **MS. b, Phase II (qualification) for 554 samples (444 T + 98 N + 12 Pan) divided into training**
 90 **(328 T + 82 N + 12 Pan) and validation (116 T + 16 N) sets measured by UHPSFC/MS,**
 91 **shotgun MS (LR and HR), and RP-UHPLC/MS at 3 different laboratories. c, Phase III**
 92 **(verification) for 830 samples (546 T + 262 N + 22 Pan) divided into training (430 T + 246 N**
 93 **+ 22 Pan) and validation (116 T + 16 N) sets measured by UHPSFC/MS for samples obtained**
 94 **from 4 collection sites.**

95 In the present study, we investigated the potential of comprehensive lipidomic
 96 profiling of human serum for PDAC detection. In most cases, the monitoring of single lipid
 97 species did not provide a reliable differentiation between cases and controls. Lipid species and


98 classes are interrelated, therefore a multi-analyte approach reflecting the whole lipidome
99 provides a stronger experimental design for clinical diagnostics. The overall methodologic
100 setup is described in Fig. 1 and in Methods. Exogenous lipid class internal standards (IS) were
101 added to serum before liquid-liquid extraction (Supplementary Table 1). Prepared extracts
102 were analyzed by several MS approaches in individual study phases²¹ (Fig. 1). The analytical
103 validation of quantitative methods was performed in the Phase I in accordance with
104 bioanalytical validation guidelines^{22,23} including two steps of quality control (details in
105 Methods)²⁴. Lipidomic MS data were processed using in-house script^{17,18}, and then
106 statistically evaluated by multivariate data analysis. The data set was split into training and
107 validation sets. The training set was used for building statistical models, which were then
108 applied for the prediction of samples from the validation set to verify the method performance
109 for samples with unknown health status. The initial Phase I included 364 PDAC patients and
110 healthy control samples, which were analyzed by ultrahigh-performance supercritical fluid
111 chromatography (UHPSFC)/MS^{24,25}, shotgun MS, and matrix-assisted laser
112 desorption/ionization (MALDI)-MS²⁶. Small differences were observed in the lipidome
113 between males and females, therefore gender separated statistical models were further used in
114 this work (Extended Data Fig. 1). Subsequently, an extended cohort of 554 samples was
115 analyzed in parallel by three independent laboratories and four different MS based approaches
116 (Phase II). Finally, 830 samples from four collection sites were analyzed by UHPSFC/MS
117 (Phase III). The method potential for diagnostic and prognosis purposes was evaluated with
118 advanced multivariate and univariate biostatistical tools. Molar concentrations (nmol/mL) of
119 all quantified lipid species (Supplementary Table 2) were used for all statistical analyses and
120 visualizations (Supplementary Tables 3 – 5). An overview of all human subjects and clinical
121 information was provided in Supplementary Tables 6 and 7.

122 The statistical evaluation of UHPSFC/MS and shotgun MS data in the Phase I showed
123 a partial discrimination between cases and controls in principal component analysis (PCA)

124 score plots and distinct group differentiation when using supervised orthogonal projections to
125 latent structures discriminant analysis (OPLS-DA) models (Extended Data Fig. 1b,c and
126 2a,b). The predicted response values for training and validation sets obtained from OPLS-DA
127 models based on the training set were used for building receiver operating characteristic
128 (ROC) curves. The area under the curve (AUC) values were over 0.99 for the training set and
129 over 0.93 for the validation set (Extended Data Fig. 2c,d). Box plots for SM 41:1 illustrated
130 the same trend for both methods (Extended Data Fig. 2e,f). MALDI-MS, performed on a
131 limited number of 64 samples, provided complementary information about the down-
132 regulation of some anionic glycosphingolipids, such as sulfatides (Extended Data Fig. 2g,h).
133 However, MALDI-MS measurements were not continued in the next phases, as the approach
134 is semi-quantitative.

135 The goal of the Phase II was to verify the results obtained in the Phase I by
136 independent laboratories. The extended cohort of 554 samples was measured by four different
137 MS based methods (UHPSFC/MS, shotgun MS with low-resolution (LR) and high-resolution
138 (HR), and RP-UHPLC/MS) with different lipidomic coverage (Extended Data Fig. 3). Results
139 from Phases II and III were normalized to reported values of lipid species concentrations²⁷ in
140 the NIST reference material according to previously published work²⁸ (Supplementary Tables
141 4 and 5). ROC curves (Fig. 2a-d), OPLS-DA score plots, sensitivity, specificity, and accuracy
142 prepared separately for males (Extended Data Fig. 4a-h) and females (Extended Data Fig. 5a-
143 h) indicated a clear discrimination of case and control groups for both training and validation
144 sets. Box plots constructed for the most significantly dysregulated lipid species (Fig. 2e-g,
145 Extended Data Fig. 4i, 5i, and 6) revealed a mutual comparability of molar concentrations
146 from individual laboratories, despite the use of different approaches for the sample
147 preparation and lipidomic quantitation. Based on the Phase II results, we hypothesize that
148 outcomes should be reproducible for other laboratories experienced in the lipidomic analysis.
149 An important issue for PDAC screening is the differentiation between PDAC and chronic

150 pancreatitis patients (Extended Data Fig. 4i and 5i). Although, lipid profiles of chronic
151 pancreatitis patients are comparable to healthy controls, the number of collected blood
152 samples was not yet sufficient to draw significant conclusions, but this should be studied for a
153 larger number of subjects within planned clinical validation.




154

155 **Fig. 2. Comparison of Phase II results obtained at three different laboratories using four**
156 **mass spectrometry based approaches.** ROC curves for males (M) and females (F) in
157 training (Tr.) and validation (Va.) sets: **a**, UHPSFC/MS, **b**, shotgun MS (LR), **c**, shotgun MS
158 (HR), and **d**, RP-UHPLC/MS. Box plots of lipid concentrations normalized with the NIST
159 reference material for samples obtained from PDAC patients (443 T) and healthy controls (95
160 N) of both genders including both validation and training sets: **e**, SM 41:1, **f**, LPC 18:2, and **g**,
161 Cer 41:1 for UHPSFC/MS (Method 1), shotgun MS (LR) (Method 2), shotgun MS (HR)
162 (Method 3), and RP-UHPLC/MS (Method 4).

163 In the Phase III, we investigated the method sensitivity for different blood collection
164 sites, applicability for the early stage (T1 or T2) screening, effects of surgery, systemic
165 therapy, and diabetes mellitus on lipidomic profiles. Statistical models for males (Fig. 3) and

166 females (Extended Data Fig. 7 and 8a) included 830 subjects from four collections sites,
 167 before and during the treatment, before and after the surgery, without and with diabetes
 168 mellitus. PCA score plots indicated minor group differentiation (Fig. 3a and Extended Data
 169 Fig. 7a), but OPLS-DA (Fig. 3b and Extended Data Fig. 7b) captured differences between
 170 PDAC and controls, as illustrated by sensitivity, specificity, and accuracy values (Fig. 3c,
 171 Extended Data Fig. 7c, and Supplementary Table 8). Lipid species with the highest influence
 172 on group clustering were selected based on S-plots (Fig. 3d and Extended Data Fig. 7d), box
 173 plots (Extended Data Fig. 6), and statistical tests (Supplementary Table 9), and listed with
 174 their fold changes, p-values, T-values, and variable influence of projection (VIP) values. Heat
 175 maps were generated based on the most dysregulated lipids (Fig. 3e and Extended Data Fig.
 176 7e).



177

178 **Fig. 3. Results for the lipidomic profiling of male serum samples from PDAC patients**
 179 **(T) and healthy controls (N) in the Phase III. a, PCA for the training set (219 T + 122 N).**


180 **b**, OPLS-DA for the training set (219 T + 122 N). Individual samples are colored according to
181 tumor (T) stage: T1 - yellow, T2 - orange, T3 - red, T4 - rose, and Tx - brown (no information
182 about the stage was provided). **c**, Sensitivity (red), specificity (blue), and accuracy (green) for
183 the training (219 T + 122 N) and validation (56 T + 6 N) sets. **d**, S-plot for the training set
184 with the annotation of most up-regulated (red) and down-regulated (blue) lipid species. **e**,
185 Heat map for both training and validation sets (275 T + 128 N). **f**, OPLS-DA for early stages
186 T1+T2, age aligned (mean age is 65 ± 4 years for N and 67 ± 4 for T), and number aligned
187 (39 T + 39 N). This graph includes both genders.

188 For PDAC screening, the key issue is the performance for early stage cancer detection,
189 because the clinical utility of such laboratory test for late stage is not likely. Unfortunately,
190 early stage PDAC patients typically account for a small subgroup among all cases, but all 15
191 males and 23 females with T1 classification in our study are correctly assigned to cancer
192 group (Supplementary Table 10). We prepared OPLS-DA model solely for T1 and T2 tumors,
193 merging males and females into one set to reach a sufficient number of subjects for better
194 robustness and compared with age and number aligned healthy controls without any treatment
195 (Fig. 3f). This model supported the observation from other graphs that early stage patients
196 were assigned with the same accuracy as for late phases (Extended Data Fig. 4a-d and 5a-d).
197 The prediction of health status in the validation set is based on predicted response values
198 calculated from OPLS-DA model in SIMCA software (Supplementary Table 10), where
199 values ≤ 0.5 are classified as normal, while values > 0.5 are predicted as PDAC (Extended Data
200 Fig. 7f). Regions > 0.75 and < 0.25 provide a very high level of confidence. On contrary, the
201 region $0.4 - 0.6$ has the higher level of uncertainty, and the majority of false classifications
202 belongs to this middle region. The approach will be used for the future screening, when the
203 clinician will obtain positive/negative output with based on predicted response values together
204 with a single number from the interval $< 0 - 1 >$ indicating the confidence of the prediction.

205 The most common chronic disease of pancreas is chronic pancreatitis, therefore
206 concentrations of the most dysregulated lipids SM 41:1 and Cer 41:1 were compared among
207 pancreatitis, PDAC, and healthy controls (Extended Data Fig. 8b,c). Lipid profiles of PDAC
208 patients before and after surgery did not show any visible changes (Extended Data Fig. 8d-f),
209 which suggests that PDAC might be a systemic disease, and that tumor removal does not
210 cause immediate return of lipidomic profile to the premorbid condition. Medical treatment did
211 not affect lipid profiles of serum samples either (Extended Data Fig. 8g,h). Subjects with
212 diabetes mellitus were included in both case and control groups, and these cases do not
213 exhibit any measurable effect on the cluster discrimination, as illustrated by box plots for SM
214 41:1 as the most dysregulated lipid (Extended Data Fig. 8i). OPLS-DA models (Extended
215 Data Fig. 8j,k) were prepared for patients before any treatment and groups of age matched
216 healthy controls to exclude any possible biases caused by treatment. The accuracy over 90%
217 and the same patterns of dysregulated lipids show that the actual treatment did not cause
218 relevant changes in lipid profiles.

219 From a biological point of view, the altered lipid metabolism may originate from
220 tumor cells, tumor stroma, apoptotic cells, and organs affected by PDAC metastatic spread.
221 An immune response of the organism may also be involved. All these processes can naturally
222 contribute to the observed cancer lipidomic phenotype. In measurements from all involved
223 laboratories, we observed a clear down-regulation of multiple lipid species in the serum of
224 PDAC patients (Extended Data Fig. 9), such as decreased levels of most very long chain
225 monounsaturated sphingomyelins and ceramides. These changes could be linked to the *KRAS*-
226 driven metabolic switch²⁹. In this context, alterations in sphingolipids concentrations deserve
227 attention, as the normal metabolism of sphingomyelins might be necessary to maintain *KRAS*
228 function³⁰. Targeted biological investigations are needed to explain the mechanism of lipid
229 alterations in the serum of PDAC patients, but it will require the development of suitable
230 animal models in the future.

231 Finally, we investigated the potential of lipids for prognostic purposes using Kaplan–
232 Meier plots, which enabled the visualization of individual parameters on the survival
233 prognosis from the lifetime data based on non-parametric statistics. The correlation of gender
234 ($p=0.077$) was not statistically significant (Extended Data Fig. 10a,b), but concentrations of
235 the following lipids exhibited a significant effect ($p<0.05$) on the survival based on the data
236 from all participating laboratories (Fig. 4 a-c, Extended Data Fig. 10b-h, and Supplementary
237 Table 11). LPC18:2 was positively correlated with survival, which is in agreement with the
238 previous work¹³. In contrast, Cer 36:1, Cer 38:1, Cer 42:2, PC 32:0, PC O-38:5, and SM 42:2
239 were negatively correlated with the survival. CA 19-9 had a strong negative correlation with
240 the survival function (Extended Data Fig. 10i). Cox proportional-hazards model was another
241 regression tool used for the visualization of associations among survival time and predictor
242 variables (Fig. 4d), which demonstrated that the concentration of LPC 18:2 higher than
243 median was positively correlated with survival, while the opposite trend was observed for CA
244 19-9 and PC O-38:5.



245

246 **Fig. 4. Potential of selected lipids for the survival prognosis in the Phase II measured by**
 247 **UHPSFC/MS.** Kaplan-Meier plots for: **a**, LPC 18:2 (n=128 for binary code 0, and n=72 for
 248 binary code 1), **b**, Cer 36:1 (n=89 for 0, and n=111 for 1), and **c**, PC 32:0 (n=99 for 0, and
 249 n=101 for 1). **d**, Cox proportional-hazards model for CA 19-9, PC 32:0, PC O-38:5, LPC
 250 18:2; Cer 36:1, Cer 38:1, Cer 42:2, and SM 42:2. Lipid species concentrations normalized to
 251 the NIST reference material obtained for all samples in the Phase II were converted into the
 252 binary code, whereby 0 was set for c < median and 1 for c > median (the median of
 253 concentrations was calculated for each lipid species including all samples).

254 In summary, we developed a robust and high-throughput lipidomic profiling approach
 255 for early detection of PDAC in human serum, which is applicable for screening of at least
 256 2,000 people per month on one MS system. The real clinical utility for early PDAC screening
 257 has to be confirmed in planned large prospective cohort for high-risk individuals (hereditary
 258 PDAC, newly diagnosed diabetes mellitus in patients over 50 years and with weight loss, and

259 patients with vague symptoms) including deeper investigation of other comorbidities. The
260 screening lipidomic test for PDAC will have a simple readout in the form of single number,
261 which provides a clear information on the health status for clinicians. All positive cases from
262 the lipidomic screening test must be confirmed by conventional diagnostic approaches.

263

264 **METHODS**

265 **Chemicals and standards**

266 In lab 1 (University of Pardubice, Czech Republic), solvents for sample preparation
267 and analysis, such as acetonitrile, 2-propanol, methanol (HPLC/MS grade), hexane, and
268 chloroform stabilized with 0.5-1 % ethanol (both HPLC grade), were purchased from either
269 Sigma-Aldrich (St. Louis, MO, USA) or Merck (Darmstadt, Germany), respectively. Mobile
270 phase additives (ammonium acetate, ammonium formate, and acetic acid) were purchased
271 from Sigma-Aldrich. Deionized water was obtained from a Milli-Q Reference Water
272 Purification System (Molsheim, France). Carbon dioxide of 4.5 grade (99.995%) was
273 purchased from Messer Group (Bad Soden, Germany). Non-endogenous lipids used as
274 internal standards (IS) for the quantitative lipidomic analysis were purchased either from
275 Avanti Polar Lipids (Alabaster, AL, USA), Nu-Chek (Elysian, MN, USA), or Merck. Lipid
276 concentrations used for the IS mixture are provided in the Supplementary Table 1 depending
277 on the employed method, further details for the preparation and dilution of the IS mixture
278 used for UHPSFC/MS measurements were previously published¹. The NIST SRM 1950
279 metabolite reference plasma was used as quality control (QC) sample and for normalization of
280 concentrations between different MS based methods. Furthermore, a pooled serum sample of
281 PDAC patients and healthy controls were used as QC sample. The lipid annotation used in
282 this manuscript²⁻⁴ is according to the recommendations of the Lipidomics standard initiative
283 (LSI) and given in Supplementary Table 2. The chemicals and standards mentioned above
284 were used for the sample preparation and measurements performed in lab 1.

285 In lab 2 (University Hospital of Regensburg, Germany), chloroform and 2-propanol
286 were purchased from Roth (Karlsruhe, Germany) and methanol from Merck (Darmstadt,
287 Germany). All solvents were HPLC grade. Ammonium formate and cholesteryl ester (CE)
288 standards were purchased from Sigma-Aldrich (Taufkirchen, Germany). TG and DG
289 standards were purchased from Larodan (Solna, Sweden) and dissolved in 2,2,4-
290 trimethylpentane/2-propanol (3:1, v/v). Phosphatidylcholine (PC), ceramide (Cer),
291 sphingomyelin (SM), lysophosphatidylcholine (LPC), and lysophosphatidylethanolamine
292 (LPE) standards were purchased from Avanti Polar Lipids (Alabaster, Alabama, USA), and
293 dissolved in chloroform.

294 In lab 3 (National University of Singapore), chemicals and reagents were obtained
295 from the following sources: ammonium formate, acetic acid, and butanol from Sigma-Aldrich
296 or Merck (Darmstadt, Germany); MS-grade acetonitrile and methanol from Fisher Scientific
297 (Waltham, MA, USA); lipid standards from Avanti Polar Lipids (Alabaster, AL, USA).
298 Ultrapure water (18 MΩ·cm at 25°C) was obtained from an Elga Labwater system (Lane End,
299 UK).

300

301 **Phases of the study**

302 The study is categorized into three phases in line with the recommendation in the
303 literature⁵: Phase I (discovery), Phase II (qualification), and Phase III (verification). In Phase
304 I, 364 samples were investigated for the lipidomic serum profile differentiation of PDAC
305 patients from healthy controls in the main laboratory (lab 1 - Pardubice) using UHPSFC/MS.
306 For the confirmation of results, the samples were again randomly processed and measured
307 with shotgun MS and, for a smaller subset, with MALDI-MS in lab 1. For Phase II, new
308 sample aliquots (554 samples) from the Masaryk Memorial Cancer Institute in Brno were
309 obtained, further re-aliquoted, and distributed among the laboratory at University of

310 Pardubice, Czech Republic (lab 1), laboratory at University Hospital of Regensburg, Germany
311 (lab 2), and laboratory at National University of Singapore (lab 3). Each laboratory processed
312 the sample set independently according to their preferred sample preparation method. For the
313 quantitative lipidomic serum profile analysis in all three laboratories, no specifications of the
314 applied mass spectrometry-based method were provided. The purpose was that the individual
315 laboratories should apply their preferred, optimized, and validated methods for the lipidomic
316 analysis. This experimental design is purposely selected to rule out that PDAC differentiation
317 from controls and dysregulation of specific lipids is method-or laboratory-dependent. The
318 following MS-based analytical methods were used for Phase II: UHPSFC/MS (lab 1), shotgun
319 MS with low- and high-resolution (lab 2), and RP-UHPLC/MS (lab 3). The sample
320 preparation protocol and lipidomic analysis was further developed and validated in the lab 1
321 between Phase I and Phase II, the optimized and validated conditions were applied for Phase
322 II and III^{1,6}. Phase III was performed in lab 1 using UHPSFC/MS for the serum lipidomic
323 analysis of samples obtained from different collection sites to verify that lipidomics profiling
324 is diagnostically conclusive and independent of the sample collection site. 554 samples from
325 Phase II are included in 830 samples of Phase III in lab 1.

326

327 **Serum samples**

328 Blood samples were drawn after overnight fasting. For Phase I (364 samples) and
329 Phase II (554 samples), all human serum samples and clinical data were obtained from the
330 Masaryk Memorial Cancer Institute in Brno, approved by the institutional ethical committees,
331 and all blood donors signed informed consent. The sample selection was based on the
332 availability of stored serum samples. The only exclusion criterion for healthy controls
333 (normal, N) was the absence of malignant diseases in the life-time history without any other
334 exclusion criteria for other diseases. For all PDAC patients, the disease was confirmed by

335 abdominal computed tomography and/or endoscopic ultrasound followed by needle biopsy or
336 surgical resection. All PDAC patients and healthy controls were of Caucasian ethnicity. The
337 samples were collected from 2013 to 2015. For Phase III (830 samples), serum samples and
338 clinical data were provided by the Masaryk Memorial Cancer Institute in Brno (554 samples,
339 see Phase II), by the First and Third Faculty of Medicine at the Charles University in Prague
340 (147 samples), by the University Hospital in Pilsen (31 samples) and by the Palacký
341 University and University Hospital in Olomouc (98 samples). 22 patients with chronic
342 pancreatitis (9 females and 13 males) treated at two outpatient departments were enrolled in
343 this study. The etiology of pancreatitis was either ethanol-induced or recurrent acute
344 pancreatitis. The diagnosis was confirmed by imaging methods (endoscopic ultrasound or
345 endoscopic retrograde cholangio-pancreatography). The overview and detailed description of
346 clinical data and patient characteristics are provided in Supplementary Tables 6 and 7. The
347 samples were independently processed for each method used in the study. In order to avoid
348 biases due to the sample collection, sample preparation and measurements, all samples within
349 the particular phase were processed and measured in the randomized order. The operator had
350 no information about the sample classification during the sample preparation and
351 measurements. The sample sets in all phases were divided into the training and validation sets
352 to determine the assay performance using the rigid rule defined before the study that each 6th
353 sample belongs to the validation set, and the rest constitutes the training set. The sample
354 classification for the training set was disclosed for the multivariate data analysis (MDA). The
355 classification of the validation set was disclosed after the final prediction of the validation set.

356

357 **Sample preparation**

358 Briefly, the whole blood was drawn into tubes containing no anticoagulant (Sarstedt S-
359 Monovette, Germany) and incubated at room temperature for 60 min. Then, the samples were

360 centrifuged at $1500 \times g$ for 15 min, the serum was isolated, immediately frozen and stored
361 at -80°C until the extraction.

362 The final lipid extraction protocol in lab 1 represents a modified Folch procedure
363 published earlier^{1,7}. Human serum (25 μL) and the mixture of IS (20 μL) were homogenized
364 in 3 mL of chloroform/methanol (2:1, v/v) for 15 min in an ultrasonic bath (40°C). When
365 samples reached ambient temperature, 600 μL of ammonium carbonate buffer (250 mM) was
366 added, and the mixture was ultrasonicated for 15 min. After 3 min of centrifugation (3000
367 rpm), the organic layer was removed, and 2 mL of chloroform was added to the aqueous
368 phase. After 15 min of ultrasonication and 3 min of centrifugation, the organic layers were
369 combined and evaporated under a gentle stream of nitrogen. The residue was dissolved in the
370 mixture of 500 μL of chloroform/methanol (1:1, v/v) and vortexed. The sample preparation
371 protocol in the Phase I was slightly different, because only single extraction was employed
372 without any buffer, with different IS concentrations, and only vortexing instead of
373 ultrasonication.

374 Finally, the extract was diluted 1:5 with chloroform/methanol (1:1, v/v) or 1:20 with
375 the mixture of hexane/2-propanol/chloroform (7:1.5:1.5, v/v/v) (Phase I) for the UHPSFC/MS
376 analysis, 1:8 with chloroform/methanol/2-propanol (1:2:4, v/v/v) mixture containing 7.5 mM
377 of ammonium acetate and 1% of acetic acid for the shotgun MS analysis, and 1:1 (v/v) with
378 methanol for the MALDI-MS.

379 The lipid extraction in the lab 2 was performed according to the Bligh and Dyer
380 protocol⁶ in the presence of exogenous lipid species as IS (Supplementary Table 1c) using 10
381 μL of human serum for the extraction. Chloroform phase was recovered by the pipetting robot
382 (Tecan Genesis RSP 150) and vacuum dried. Residues were dissolved in either 7.5 mM
383 ammonium acetate in methanol/chloroform (3:1, v/v) (for low-resolution tandem mass
384 spectrometry) or chloroform/methanol/2-propanol (1:2:4 v/v/v) with 7.5 mM ammonium
385 formate (for high-resolution mass spectrometry).

386 The lipid extraction in the lab 3 was performed in a randomized order using the
387 stratified randomization based on the sample group, age, gender, and BMI. The sample
388 extraction was done over three days (~230 samples / day). Human serum samples (~100 μ L
389 each) were taken out of -80°C freezer into a biosafety cabinet and thawed on ice. 10 μ L of
390 each serum sample was transferred into 1.5 mL Eppendorf tubes. In addition, 5 μ L of each
391 serum sample was pooled together, mixed, and then 10 μ L was aliquoted in 59 Eppendorf
392 tubes to constitute batch quality control (BQC) samples. Process blanks (PBLK1-4) were
393 prepared by aliquoting 10 μ L of water into 1.5 mL Eppendorf tubes for the extraction control.
394 10 μ L of commercial human plasma was pipetted into 1.5 mL Eppendorf tubes as reference
395 samples (LTR1-4). 10 μ L of NIST SRM 1950 plasma was pipetted into 1.5 mL Eppendorf
396 tubes as additional reference samples (NIST1-4). The extraction was done on all above-
397 mentioned samples as follows: Add 190 μ L of chilled butanol/methanol (1:1, v/v) containing
398 IS to the samples. Vortex each sample for 10 seconds and sonicate in ice water for 30 min.
399 Centrifuge at 14,000 relative centrifugal force for 10 min at 4°C to pellet insoluble. Transfer
400 140 μ L of supernatant into clean vials. Pool 30 μ L of lipid extract from each vial (only from
401 samples, not including BQC, NIST and LTR), mix, and aliquot into 59 vials as technical
402 quality control (TQC) samples. The TQC extract was diluted with chilled butanol/methanol
403 (1:1, v/v) to prepare 80%, 60%, 40% and 20% diluted TQC solution, which were used to
404 assess the instrument response linearity. The lipid extracts in LC/MS vials were kept in the -
405 80°C freezer until LC/MS/MS analysis. On the day of analysis, LC/MS vials were taken out
406 of the freezer, thawed at room temperature for 30 min, sonicated in ice-cold water for 15 min,
407 and injected into LC/MS/MS.

408

409 **Measurements of CA 19-9**

410 CA19-9, a mucin corresponding to the sialylated Lewis (Le)^a blood group antigen, was
411 quantitatively determined using the electro-chemoluminescence immunoassay Elecsys[®]

412 (Roche, Rotkreuz, Switzerland) according to manufacturer instructions. The CA19-9 test was
413 performed only for PDAC samples. The cut-off value for the CA 19-9 test is 37 U/mL,
414 therefore all values over 37 U/mL were classified as PDAC.

415

416 **UHPSFC/ESI-MS conditions (lab 1)**

417 UHPSFC/MS measurements were carried out on the Acquity Ultra Performance
418 Convergence Chromatography (UPC²) system coupled to the hybrid quadrupole-traveling
419 wave ion mobility time-of-flight mass spectrometer Synapt G2-Si from Waters by using the
420 commercial interface kit (Waters, Milford, MA, USA). The chromatographic settings were
421 used with minor improvements from previously published methods^{1,8}. The main difference is
422 that the data were recorded in the continuum mode. The peptide leucine enkephalin was used
423 as the lock mass with the scan time of 0.1 s and the interval of 30 s. The lock mass was
424 scanned but not automatically applied. The noise reduction was performed on raw files using
425 the Waters compression tool, and then data was lock mass corrected as well as converted into
426 the centroid data using the exact mass measure tool from Waters. For the data pre-processing,
427 the MarkerLynx software from Waters was used. Further data processing was done by
428 LipidQuant software available on figshare (<https://figshare.com/s/cc087785ca362af7118e>).

429

430 **Shotgun MS conditions (lab 1)**

431 Shotgun experiments were performed on the quadrupole-linear ion trap mass
432 spectrometer 6500 QTRAP (Sciex, Concord, ON, Canada) equipped with the ESI probe.
433 Characteristic precursor ion (PI) and neutral loss (NL) scan events were used for the detection
434 of individual lipid classes and previously reported MS settings applied⁹. For the data analysis,
435 all observed ions in the positive-ion mode characterized by m/z values, type of scan, and ion

436 intensities were exported as .txt data file and further processed using the LipidQuant software
437 available on figshare (<https://figshare.com/s/b28049603a4f361c818b>).

438

439 **MALDI-MS conditions (lab 1)**

440 MALDI matrix 9-aminoacridine (Sigma-Aldrich, St. Louis, MO, USA) was dissolved
441 in methanol – water mixture (4:1, v/v) to the concentration of 5 mg/mL. Diluted lipid extracts
442 of serum were mixed with matrix (1:1, v/v). The volume of 1 μ L of extract/matrix mixture
443 was deposited on the target plate using the dried droplet crystallization. A small aliquot of
444 chloroform was applied onto MALDI plate spots before the application of diluted
445 extract/matrix mixture to avoid the drop spreading. Mass spectra were measured on the high-
446 resolution MALDI mass spectrometer LTQ Orbitrap XL (Thermo Fisher Scientific, Waltham,
447 MA, USA) equipped with the nitrogen UV laser (337 nm, 60 Hz) with a beam diameter of
448 about 80 μ m \times 100 μ m. The LTQ Orbitrap instrument was operated in the negative-ion mode
449 over a normal mass range m/z 400 - 2000 with the mass resolution 100,000 (full width at half-
450 maximum definition at m/z 400). The zig-zag sample movement with 250 μ m step size was
451 used during the data acquisition. The laser energy corresponds to 15% of maximum, and 2
452 microscans/scan with 2 laser shots per microscan at 36 different positions were accumulated
453 for each measurement to achieve a reproducible signal. Each sample (spotted matrix and lipid
454 extract mixture) was spotted five times. The total acquisition time for one sample, including
455 measurements of five consecutive spots, was 10 min. Each measurement was represented by
456 one average MALDI-MS spectrum with thousands of m/z values. The automatic peak
457 assignment was subsequently performed, and m/z peaks were matched with deprotonated
458 molecules from a database created during the identification procedure using the LipidQuant
459 software available on figshare (<https://figshare.com/s/cb071be45cd91a7c90e2>). This peak
460 assignment resulted in the generation of the list of present m/z of studied lipids with the

461 average intensities over all spectra, which was used for the further IS or relative normalization
462 and the statistical evaluation.

463

464 **Shotgun MS conditions (lab 2)**

465 The analysis of lipids was performed by the direct flow injection analysis (FIA) using
466 a triple quadrupole (QqQ) mass spectrometer (FIA-MS/MS) and a Fourier Transform (FT)
467 hybrid quadrupole – Orbitrap mass spectrometer (FIA-FTMS). FIA-MS/MS was performed in
468 the positive ion mode using the analytical setup and the strategy described previously^{10,11}. The
469 fragment ion of m/z 184 was used for phosphatidylcholines (PC), sphingomyelins (SM)¹¹, and
470 lysophosphatidylcholines (LPC)¹². The following neutral losses were applied for:
471 phosphatidylethanolamines (PE) - 141, phosphatidylserines (PS) - 185, phosphatidylglycerols
472 (PG) – 189, and phosphatidylinositols (PI) – 277 (ref.¹³). PE-based plasmalogens (PE-P) were
473 analyzed according to the principles described by Zemski-Berry¹⁴. Sphingosine based
474 ceramides (Cer) and hexosylceramides (HexCer) were analyzed using the fragment ion of m/z
475 264 (ref.¹⁵).

476 FIA-FTMS setup was described in details in previous work¹⁶. Triacylglycerols (TG),
477 diacylglycerols (DG), and cholesteryl esters (CE) were recorded in the positive ion mode in
478 m/z range 500 - 1000 for 1 min with a maximum injection time (IT) of 200 ms, an automated
479 gain control (AGC) of $1 \cdot 10^6$, 3 microscans, and a target resolution of 140,000 (at 200 m/z).
480 The mass range of negative ion mode was split into two parts. LPC and
481 lysophosphatidylethanolamines (LPE) were analyzed in the range m/z 400 - 650. PC, PE, PS,
482 SM, and ceramides were measured in m/z range 520 - 960. Multiplexed acquisition (MSX)
483 was used for $[M+NH_4]^+$ of free cholesterol (FC) (m/z 404.39) and D7-cholesterol (m/z 411.43)
484 using 0.5 min of the acquisition time with the normalized collision energy of 10 %, IT of 100
485 ms, AGC of $1 \cdot 10^5$, the isolation window of 1 Da, and the target resolution of 140,000. Data

486 processing details were described in H6ring *et al.* using the ALEX software^{16,17}, which
487 includes the peak assignment procedure and the intensity picking. The extracted data were
488 exported to Microsoft Excel 2010 and further processed by the self-programmed Macros
489 available on figshare (<https://figshare.com/s/e336bdf3a52f04c2de1f>).

490 Lipid species were annotated according to the shorthand notation of lipid structures
491 derived from mass spectrometry². For QqQ glycerophospholipid species, the annotation was
492 based on the assumption of even numbered carbon chains only. SM species annotation is
493 based on the assumption that a sphingoid base with two hydroxyl groups is present.

494

495 **RP-UHPLC/MS/MS conditions (lab 3)**

496 The RP-UHPLC/MS/MS analysis was performed on the Agilent UHPLC 1290 liquid
497 chromatography system connected to the Agilent QqQ 6495A mass spectrometer. The Agilent
498 Eclipse Plus C18 column (100 mm × 2.1 mm, 1.8 μm) was used for the LC separation. The
499 mobile phases A (30% acetonitrile – 20% isopropanol – 50% 10mM ammonium formate in
500 H₂O, v/v/v + 0.1% formic acid) and B (90% isopropanol – 9% acetonitrile – 1% 10mM
501 ammonium formate in H₂O, v/v/v + 0.1% formic acid) were used for both positive and
502 negative ionization. The following gradient was applied: 0 min 15% B, 2.5 min 50% B, 2.6
503 min 57% B, 9 min 70% B, 9.1 min 93% B, 11 min 96% B, 11.1 min 100% B, 11.9 min 100%
504 B, and 12.0 min 15% B, held for 3 min (total runtime of 15 min). The column temperature
505 was maintained at 45°C. The flow rate was set to 0.4 mL/min and the sample injection
506 volume was 2 μL.

507 The spray voltage was set to 3.5 kV in the positive ionization mode and 3 kV in the
508 negative ionization mode. The nozzle voltage was set at 1 kV. The drying gas temperatures
509 were kept at 150°C. The sheath gas temperature was 250°C. The drying gas and sheath gas

510 flow rates were 14 L/min and 11 L/min, respectively. The nebulizer gas setting was 20 psi.
511 The iFunnel high- and low-pressure RF were 180 V and 160 V, respectively, in the positive
512 ionization mode and 90 V and 60 V, respectively, in the negative ionization mode. The MRM
513 list is provided in the Supplementary Table 12.

514 Quantitative data were extracted by using the Agilent MassHunter Quantitative
515 Analysis (QqQ) software. The data were manually curated to ensure that the software
516 integrated the right peaks. Peak areas of extracted ion chromatograms peaks for each MRM
517 transition were exported to Microsoft Excel. Peak areas were normalized to peak areas of IS
518 using an in-house R script. The data quality was assessed using the following criteria, MRM
519 transitions kept for the analysis had to satisfy: coefficient of variations (CoV) measured across
520 the QC injections $< 20\%$, linearity TQC dilution series Pearson $R^2 > 0.80$, signal in processed
521 blanks $< 10\%$ of the signal observed in the QC. Data are available at figshare:
522 <https://figshare.com/s/1fd10f273b049b93fa24>

523

524 **Method validation and quality control (lab 1)**

525 The UHPSFC/MS method was validated in line with FDA and EMA guidelines, as
526 previously published¹. Solvent blanks and QC samples were regularly measured after each 40
527 samples. For the QC samples, a pooled serum sample and the NIST SRM reference plasma
528 sample were extracted and aliquoted. Furthermore, a mixture of naturally occurring lipid
529 species were used as a system suitability standard. In order to assess the instrumental state, the
530 instrument stability and the sample preparation quality, the signal response of selected
531 endogenous lipids and the IS in all samples were monitored during the whole sequence. The
532 signal responses of selected lipids were plotted against the number of measured samples,
533 which allows the visualization of outliers due to the sample preparation or instrumental
534 failures. Typically, a gradual signal drop is observed for the IS caused by contamination of the

535 mass spectrometer over time.⁶ Furthermore, PCA for the lipidomic profiles in all samples was
536 performed to review for outliers and the clustering of QC samples.

537

538 **Statistical analysis**

539 SIMCA software, version 13.0 (Umetrics, Umeå, Sweden) was used to perform the
540 unsupervised PCA with unclassified samples, and the supervised OPLS-DA with the known
541 sample classification. Only scatter plots of the first and second components are presented in
542 PCA score plots. OPLS-DA separates samples into known classes and can be used for the
543 prediction. First, studied lipids were defined as variables, and samples were defined as
544 different observations and further classified, *i.e.*, for the health state, gender, and cancer stage.
545 Differences in lipid profiles between genders were observed in the Phase I (Extended Data
546 Fig. 1), therefore data sets for males and females were handled separately. The data sets were
547 pre-treated by a logarithmic transformation, centering, scaling (unit variance (UV) or Pareto
548 (Par) scaling), and evaluation of outliers. Logarithmic transformation was applied for each
549 lipid species. Centering relates relative changes of a lipid species to the average, where UV or
550 Pareto scaling compensates the concentration variance differences for lipid species. The
551 scaling was chosen with regard to improved separation of PDAC patient and control samples
552 and reduced number of outliers without using class information employing PCA. Pareto
553 scaling was superior for UHPSFC/MS, MALDI-MS, low- and high-resolution shotgun MS
554 (lab 2) and RP-UHPLC/MS (lab 3) measurements, and UV scaling for shotgun MS
555 measurements in lab 1 during Phase I. For PCA and OPLS-DA, the number of components
556 was assessed by model fit and prediction ability. In the case of too few components, the
557 differentiation of classes (*i.e.*, health state) is insufficient, while in the case of too many
558 components, the model may be overfitted, resulting in diminished prediction power. The
559 model fit was determined by the evaluation of R², which describes the variation of variables

560 (lipid species) explained by the model. The prediction ability of the model is described by Q2
561 and is estimated using a cross-validation. Cross-validation was performed by dividing the data
562 set into 7 groups, omitting one group, building the model, and predicting the omitted group.
563 This was repeated for each group, and the results of the prediction were summarized by the
564 variable Q2. For building models, components were added as long as Q2 was increasing with
565 the number of components. Finally, PCA plot was evaluated for outliers, errors in
566 measurements, clustering of QC samples as well as for the separation of sample types, *i.e.*,
567 PDAC patients vs. healthy controls. Afterwards, OPLS-DA was performed in order to
568 discriminate between PDAC patients and healthy controls. The number of predictive and
569 orthogonal components for all methods is provided in Supplementary Table 8b. A confidence
570 level on parameters of 95% was used for all models.

571 OPLS models were built for the training set for individual methods and validated by
572 the prediction of the validation set using predicted response values. The unpredicted original
573 value of Y is 0, if a human subject is without cancer, and 1 in case of PDAC (binary variable).
574 Predicted response value is continuous and computed using the last model component. Based
575 on the predicted value of Y, the sample is classified as non-cancerous subject (if predicted Y
576 ≤ 0.5) or cancerous subject (if predicted Y > 0.5). A summary of predicted response values
577 obtained for the training and validation sets with the various methods at the different clinical
578 phases is provided in the Supplementary Table 10. Depending on the correctly identified
579 healthy and cancerous samples, the selectivity, specificity, and accuracy of the model for the
580 training and validation samples were determined (Supplementary Table 8a).

581 In order to evaluate lipids of statistical significance, a two-sided two sample T-test
582 assuming unequal variances (Welch test) was performed for healthy and cancerous samples.
583 P-values < 0.05 were considered to indicate the statistical significance. The Bonferroni
584 approach was applied to all p-values for the multiple testing correction. The summary
585 statistics and average molar lipid concentrations for healthy and cancerous samples are

586 summarized in the Supplementary Tables 9a-c for all methods and study phases. Furthermore,
587 the parameter of variable influence of projection (VIP) was evaluated for each statistical
588 OPLS-DA model using the SIMCA software. Finally, only lipid species with p-values <0.05,
589 VIP values >1, and fold changes $\geq 20\%$ for molar concentrations were considered as
590 statistically important and reported in Supplementary Tables 9a-c. For the visualization of
591 differences in lipid concentrations (up- and down-regulation) between cancer and control
592 samples, box plots were constructed in R free software environment ([https://www.r-](https://www.r-project.org)
593 [project.org](https://www.r-project.org)) using ggplot2, ggpubr, and rstatix packages. In each boxplot, the median was
594 presented by a horizontal line, box represented 1st and 3rd quartile values, and whiskers stood
595 for 1.5*IQR from the median. Each measurement was plotted as jittered point value. The
596 receiver operating characteristics (ROC) curves were generated by using the package AUC in
597 R.

598 For verification of the data processing, statistical analysis and results, data were cross-
599 checked and independently reprocessed or evaluated by applying the online metabolomics
600 platform MetaboAnalyst (ver. 4.0)¹⁸.

601 For the Kaplan-Meier survival analysis and the Cox Hazard proportional analysis,
602 lipid concentrations were converted into the binary code. Therefore, the median concentration
603 of the lipid species for all samples were calculated, and individual lipid species concentrations
604 were classified to 0, when the concentration was smaller than the median concentration of all
605 samples or 1, when the concentration was bigger than the median concentration of all
606 samples. The Kaplan-Meier survival analysis plots and the Cox-Hazard proportional analysis
607 plots were generated by using the packages survival and survminer in R software.

608

609 **Outlier inspection**

610 The QC system and the PCA analysis revealed outliers. In Phase I, sample No. 355
611 was excluded from the UHPSFC/MS data set, and sample No. 210 for the shotgun MS data
612 set, due to the sample preparation failure. The repetition of the sample preparation was not
613 possible due to insufficient serum volume. In the Phase II, samples No. 246 and 500 were
614 excluded from the low resolution shotgun MS data set, and samples No. 246 and 409 from the
615 high resolution shotgun MS data set.

616

617 **Data availability**

618 All data necessary to support the conclusions are available in the manuscript or
619 supplementary information. Raw data, instructions for the software handling and the software
620 are deposited at figshare.com:

621 <https://figshare.com/s/5ddbcbf1be4a1aec966f>

622 <https://figshare.com/s/b28049603a4f361c818b>

623 <https://figshare.com/s/40f1450376cdc8d69e9a>

624 <https://figshare.com/s/cb071be45cd91a7c90e2>

625 <https://figshare.com/s/1fd10f273b049b93fa24>

626 <https://figshare.com/s/e336bdf3a52f04c2de1f>

627 <https://figshare.com/s/cc087785ca362af7118e>

628

629 **References**

- 630 1. Hur, C. et al. Early pancreatic ductal adenocarcinoma survival is dependent on size
631 positive implications for future targeted screening. *Pancreas* **45**, 1062-1066 (2016).
- 632 2. Ryan, D.P., Hong, T.S. & Bardeesy, N. Pancreatic adenocarcinoma. *N. Engl. J. Med.*
633 **371**, 1039-1049 (2014).

- 634 3. Wolrab, D. et al. Oncolipidomics: Mass Spectrometric Quantitation of Lipids in
635 Cancer Research. *Trends Anal. Chem.* **120**, 115480 (2019).
- 636 4. Holčapek, M., Liebisch & G., Ekroos, K. Lipidomic analysis. *Anal. Chem.* **90**, 4249-
637 4257 (2018).
- 638 5. Cancer treatment & survivorship facts & figures. American cancer society.
639 <https://www.cancer.org/research/cancer-facts-statistics/survivor-facts-figures.html>
640 (2016-2017).
- 641 6. Toft, J. et al. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A
642 systematic review and meta-analysis of sensitivity, specificity and diagnostic
643 accuracy. *Eur. J. Radiol.* **92**, 17-23 (2017).
- 644 7. Duffy, M.J. et al. Tumor markers in pancreatic cancer: a European group on tumor
645 markers (EGTM) status report. *Ann. Oncol.* **21**, 441–447 (2010).
- 646 8. Root, A., Allen, P., Tempst, P. & Yu, K. Protein biomarkers for early detection of
647 pancreatic ductal adenocarcinoma: progress and challenges. *Cancers* **10**, 67-78 (2018).
- 648 9. Cohen, J.D. et al. Detection and localization of surgically resectable cancers with a
649 multi-analyte blood test. *Science* **359**, 926-930 (2018).
- 650 10. Buscail, L., Bournet, B. & Cordelier, P. Role of oncogenic KRAS in the diagnosis,
651 prognosis and treatment of pancreatic cancer. *Nat. Rev. Gastroenterol. Hepatol.* **17**,
652 153–168 (2020).
- 653 11. Jones S., et al. Core signaling pathways in human pancreatic cancers revealed by
654 global genomic analyses. *Science* **321**, 1801–1806 (2008).
- 655 12. Bryant, K., Mancias, J., Kimmelman, A. & Der, C. KRAS: feeding pancreatic cancer
656 proliferation. *Trends Biochem. Sci.* **39**, 91-100 (2014).

- 657 13. Kamphorst, J. et al. Hypoxic and Ras-transformed cells support growth by scavenging
658 unsaturated fatty acids from lysophospholipids. *Proc. Natl. Acad. Sci. USA*. **110**,
659 8882-8887 (2013).
- 660 14. Salloum, D. et al. Mutant ras elevates dependence on serum lipids and creates
661 a synthetic lethality for rapamycin. *Mol. Cancer Ther.* **13**, 733-741 (2014).
- 662 15. Rozeveld, C.N., Johnson, K.M., Zhang, L., Razidlo, G.L. KRAS Controls Pancreatic
663 Cancer Cell Lipid Metabolism and Invasive Potential through the Lipase HSL. *Cancer*
664 *Res.* **80**, 4932-4945 (2020).
- 665 16. Wenk, M.R. Lipidomics: new tools and applications. *Cell* **143**, 888-895 (2010).
- 666 17. Cífková, E. et al. Correlation of lipidomic composition of cell lines and tissues of
667 breast cancer patients using hydrophilic interaction liquid chromatography –
668 electrospray ionization mass spectrometry and multivariate data analysis. *Rapid*
669 *Commun. Mass Spectrom.* **31**, 253-263 (2017).
- 670 18. Cífková, E. et al. Determination of lipidomic differences between human breast cancer
671 and surrounding normal tissues using HILIC-HPLC/ESI-MS and multivariate data
672 analysis. *Anal. Bioanal. Chem.* **407**, 991-1002 (2015).
- 673 19. Bandu, R., Mok, H.J. & Kim, K.P. Phospholipids as cancer biomarkers: mass
674 spectrometry-based analysis. *Mass Spectrom. Rev.* **37**, 107-138 (2018).
- 675 20. Heiskanen, L.A., Suoniemi, M., Ta, H.X., Tarasov, K. & Ekroos, K. Long-term
676 performance and stability of molecular shotgun lipidomic analysis of human plasma
677 samples. *Anal. Chem.* **85**, 8757–8763 (2013).
- 678 21. Rifai, N., Gillette, M.A., Carr, S.A. Protein biomarker discovery and validation: the
679 long and uncertain path to clinical utility. *Nat. Biotechnol.* **24**, 971-983 (2006).

- 680 22. Guideline on bioanalytical method validation. Committee for medicinal products for
681 human use (CHMP).
682 [http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_d
684 etail.jsp?webContentId=WC500109686%26mid=WC0b01ac058009a3dc](http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_d
683 etail.jsp?webContentId=WC500109686%26mid=WC0b01ac058009a3dc) (First
published 2011, last updated 2015).
- 685 23. Food and drug administration guidance for industry: bioanalytical method validation.
686 US Department of health and human services. Center for drug evaluation and research:
687 Rockville, MD.
688 <https://www.fda.gov/ForIndustry/IndustryNoticesandGuidanceDocuments/default.htm>
689 (2001).
- 690 24. Wolrab, D. et al. , Determination of one year stability of lipid plasma profile and
691 comparison of blood collection tubes using UHPSFC/MS and HILIC-UHPLC/MS.
692 *Anal. Chim. Acta* **1137**, 74-84 (2020).
- 693 25. Lída, M. & Holčapek, M. High-throughput and comprehensive lipidomic analysis
694 using ultrahigh-performance supercritical fluid chromatography–mass spectrometry.
695 *Anal. Chem.* **87**, 7187–7195 (2015).
- 696 26. Jirásko, R. et al. MALDI Orbitrap mass spectrometry profiling of dysregulated
697 sulfoglycosphingolipids in renal cell carcinoma tissues. *J. Amer. Mass Spectrom. Soc.*
698 **28**, 1562-1574 (2017).
- 699 27. Burla, B. et al. MS-based lipidomics of human blood plasma: a community-initiated
700 position paper to develop accepted guidelines. *J Lipid Res.* **59**, 2001-2017 (2018).
- 701 28. Triebel, A. et al. Shared reference materials harmonize lipidomics across MS based
702 detection platforms and laboratories. *J. Lipid Res.* **61**, 105e115 (2020).

- 703 29. Daemen, A. et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas
704 into subtypes with distinct sensitivities to metabolic inhibitors. *Proc. Natl. Acad. Sci.*
705 *USA* **112**, E4410-E4417 (2015).
- 706 30. van der Hoeven, D. et al. Sphingomyelin Metabolism Is a Regulator of K-Ras
707 Function. *Mol Cell Biol.* **38**, e00373-17 (2018).

708

709 **References Methods**

- 710 1. Wolrab, D., Chocholoušková, M., Jirásko, R., Peterka, O. & Holčápek, M. Validation
711 of lipidomic analysis of human plasma and serum by supercritical fluid
712 chromatography–mass spectrometry and hydrophilic interaction liquid
713 chromatography–mass spectrometry. *Analytical and Bioanalytical Chemistry* **412**,
714 2375-2388 (2020).
- 715 2. Liebisch, G., et al. Shorthand notation for lipid structures derived from mass
716 spectrometry. *Journal of Lipid Research* **54**, 1523-1530 (2013).
- 717 3. Fahy, E., et al. Update of the LIPID MAPS comprehensive classification system for
718 lipids. *Journal of Lipid Research* **50**, S9-S14 (2009).
- 719 4. Fahy, E., et al. A comprehensive classification system for lipids. *Journal of Lipid*
720 *Research* **46**, 839-862 (2005).
- 721 5. Rifai, N., Gillette, M.A., Carr, S.A. Protein biomarker discovery and validation: the
722 long and uncertain path to clinical utility. *Nature Biotechnology* **24**, 971-983 (2006).
- 723 6. Wolrab, D., et al. Determination of one year stability of lipid plasma profile and
724 comparison of blood collection tubes using UHPSFC/MS and HILIC-UHPLC/MS.
725 *Analytica Chimica Acta* **1137**, 74-84 (2020).
- 726 7. Bligh, E.G. & Dyer, W.J. A Rapid method of total lipid extraction and purification.
727 *Canadian Journal of Biochemistry and Physiology* **37**, 911-917 (1959).

- 728 8. Lísa, M., Cífková, E., Khalikova, M., Ovčačiková, M. & Holčapek, M. Lipidomic
729 analysis of biological samples: Comparison of liquid chromatography, supercritical
730 fluid chromatography and direct infusion mass spectrometry methods. *Journal of*
731 *Chromatography A* **1525**, 96-108 (2017).
- 732 9. Cífková, E., *et al.* Lipidomic differentiation between human kidney tumors and
733 surrounding normal tissues using HILIC-HPLC/ESI-MS and multivariate data
734 analysis. *Journal of Chromatography B* **1000**, 14-21 (2015).
- 735 10. Liebisch, G., *et al.* High throughput quantification of cholesterol and cholesteryl ester
736 by electrospray ionization tandem mass spectrometry (ESI-MS/MS). *Biochimica et*
737 *Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids* **1761**, 121-128 (2006).
- 738 11. Liebisch, G., Lieser, B., Rathenberg, J., Drobnik, W. & Schmitz, G. High-throughput
739 quantification of phosphatidylcholine and sphingomyelin by electrospray ionization
740 tandem mass spectrometry coupled with isotope correction algorithm. *Biochimica et*
741 *Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids* **1686**, 108-117 (2004).
- 742 12. Liebisch, G., Drobnik, W., Lieser, B. & Schmitz, G. High-Throughput Quantification
743 of Lysophosphatidylcholine by Electrospray Ionization Tandem Mass Spectrometry.
744 *Clinical Chemistry* **48**, 2217-2224 (2002).
- 745 13. Matyash, V., Liebisch, G., Kurzchalia, T.V., Shevchenko, A. & Schwudke, D. Lipid
746 extraction by methyl-tert-butyl ether for high-throughput lipidomics. *Journal of Lipid*
747 *Research* **49**, 1137-1146 (2008).
- 748 14. Berry, K.A.Z. & Murphy, R.C. Electrospray ionization tandem mass spectrometry of
749 glycerophosphoethanolamine plasmalogen phospholipids. *Journal of the American*
750 *Society for Mass Spectrometry* **15**, 1499-1508 (2004).
- 751 15. Liebisch, G., *et al.* Quantitative measurement of different ceramide species from crude
752 cellular extracts by electrospray ionization tandem mass spectrometry (ESI-MS/MS).
753 *Journal of Lipid Research* **40**, 1539-1546 (1999).

- 754 16. Höring, M., Ejlsing, C.S., Hermansson, M. & Liebisch, G. Quantification of
755 Cholesterol and Cholesteryl Ester by Direct Flow Injection High-Resolution Fourier
756 Transform Mass Spectrometry Utilizing Species-Specific Response Factors.
757 *Analytical Chemistry* **91**, 3459-3466 (2019).
- 758 17. Husen, P., *et al.* Analysis of Lipid Experiments (ALEX): A Software Framework for
759 Analysis of High-Resolution Shotgun Lipidomics Data. *PLOS ONE* **8**, e79736 (2013).
- 760 18. Chong, J. & Xia, J. MetaboAnalystR: an R package for flexible and reproducible
761 analysis of metabolomics data. *Bioinformatics* **34**, 4313-4314 (2018).

762

763 **Acknowledgments**

764 The project was funded by the project 18-12204S (the Czech Science Foundation). L.K.
765 acknowledges the support of institutional program of the Charles University in Prague
766 (UNCE 204064). R.H. acknowledges the support of MEYS – BBMRI-CZ LM2018125 (the
767 Ministry of Education, Youth and Sports of the Czech Republic) and MH CZ - DRO (MMCI,
768 00209805, the Ministry of Health of the Czech Republic) projects.

769 **Author contributions**

770 M.H., D.W., R.J., and E.C. prepared the design of experiments. D.W., M. Ch., and O.P.
771 performed sample preparation. D.W. analyzed sample by UHPSFC/MS, E.C. by shotgun MS,
772 and R.J. by MALDI-MS. M. Hör., D.M., G.L., R.B., M.R.W., and A.C.G. performed analysis
773 and data evaluation in cooperating laboratories. E.C. developed the software for data
774 evaluation. D.W., R.J., T.H., E.C., J.I., and G.V.T. processed data and performed statistical
775 analysis. L.K., R.K., D.F., and R.A. discussed observed changes. R.H., P.K., I.N., P.Š., J.Š.,
776 R.K., and B.M. obtained and provided serum samples and corresponding data. M.H., D.W.,
777 and R.J. prepared the first draft of manuscript. D.W., R.J., J.I., and R.K. prepared figures.

778 M.H. was responsible for funding and supervision of this study. All co-authors read and
779 approved the manuscript.

780 **Competing interests**

781 M.H., E.C., R.J., and D.W. are listed as inventors on patent EP 3514545 related to this work.

782 **Extended Data - Figures legends**

783

784 **Extended Data Fig. 1. Effect of gender separation on the quality of OPLS-DA models**
785 **used for the differentiation of human serum samples obtained from PDAC patients (T)**
786 **and healthy controls (N) for the training set using UHPSFC/MS in the Phase I. a, Both**
787 **genders. b, Males. c, Females. d, Specificity, sensitivity, and accuracy for individual models.**

788

789 **Extended Data Fig. 2. Results for the Phase I obtained in the lab 1.** Individual samples are
790 colored according to tumor (T) stage: T1 - yellow, T2 - orange, T3 - red, T4 - rose, and Tx -
791 brown (no information about the stage was provided). **a**, OPLS-DA for males measured with
792 shotgun MS for the training set (104 T + 30 N). **b**, OPLS-DA for females measured with
793 shotgun MS for the training set (157 T + 49 N). ROC curves for males (M) and females (F) in
794 training (Tr.) and validation (Va.) sets: **c**, UHPSFC/MS, and **d**, shotgun MS. Box plots for
795 molar concentration in human serum from PDAC patients (T) and healthy controls (N) for
796 males (M) and females (F): **e**, SM 41:1 measured by UHPSFC/MS, **f**, SM 41:1 measured by
797 shotgun MS (LR), for both box plots for males (104 T and 30 N) and females (109 T and 49
798 N), **g**, SHexCer 41:1(OH) measured by MALDI-MS, and **h**, SHexCer 40:1(OH) measured by
799 MALDI-MS, for both box plots for males (15 T and 14 N) and females (18 T and 19 N)

800

801

802 **Extended Data Fig. 3. Summary of quantified lipid species for particular lipid classes.**
803 Method 1 – UHPSFC/MS measured by lab 1 (n=202), Method 2 – shotgun MS with low-
804 resolution (LR) measured by lab 2 (n=232), Method 3 – shotgun MS with high-resolution
805 (HR) measured by lab 2 (n=183), and Method 4 – RP-UHPLC/MS measured by lab 3

806 (n=431). Annotation of lipid classes: CE – cholesteryl esters, Cer – ceramides, DG –
807 diacylglycerols, TG – triacylglycerols, PC – phosphatidylcholines, LPC –
808 lysophosphatidylcholines, PE – phosphatidylethanolamines, PI – phosphatidylinositols, and
809 SM – sphingomyelins.

810

811 **Extended Data Fig. 4. Results for the lipidomic profiling of male serum samples from**
812 **PDAC patients and healthy controls in the Phase II.** OPLS-DA for molar concentrations of
813 lipid species obtained for the training set: **a**, UHPSFC/MS (166 T + 33 N), **b**, shotgun MS
814 (LR) (165 T + 33 N), **c**, shotgun MS (HR) (164 T + 33 N), and **d**, RP-UHPLC/MS (166 T +
815 33 N). Individual samples are colored according to their tumor (T) stage: T1 – yellow, T2 –
816 orange, T3 – red, T4 – rose, Tx – brown (no information about the stage was provided).
817 Sensitivity (red), specificity (blue), and accuracy (green) values in percentage for the training
818 (Tr.) and validation (Va.) sets: **e**, UHPSFC/MS, **f**, shotgun MS (LR), **g**, shotgun MS (HR),
819 and **h**, RP-UHPLC/MS. **i**, Box plots of molar lipid concentrations normalized with the NIST
820 reference material determined in PDAC patients (222 T), controls (39 N), and pancreatitis (9
821 Pan) patients including both validation and training sets for SM 41:1 using UHPSFC/MS
822 (Method 1), shotgun MS (LR) (Method 2), shotgun MS (HR) (Method 3), and RP-
823 UHPLC/MS (Method 4).

824

825 **Extended Data Fig. 5. Results for the lipidomic profiling of female serum samples from**
826 **PDAC patients (T) and healthy controls (N) in the Phase II.** OPLS-DA for molar
827 concentrations of lipid species obtained for the training set: **a**, UHPSFC/MS (161 T + 46 N),
828 **b**, shotgun MS (LR) (160 T + 46 N), **c**, shotgun MS (HR) (161 T + 46 N), and **d**, RP-
829 UHPLC/MS (161 T + 46 N). Individual samples are colored according to their tumor (T)
830 stage: T1 - yellow, T2 - orange, T3 - red, T4 - rose, and Tx - brown (no information about the

831 stage was provided). Sensitivity (red), specificity (blue), and accuracy (green) values in
832 percentage for the training and validation sets: **e**, UHPSFC/MS, **f**, shotgun MS (LR), **g**,
833 shotgun MS (HR), and **h**, RP-UHPLC/MS. **i**, Box plots of molar lipid concentrations
834 normalized with the NIST reference material determined in PDAC patients (221 T), controls
835 (56 N), and pancreatitis (3 Pan) patients including both validation and training sets for SM
836 41:1 using UHPSFC/MS (Method 1), shotgun MS (LR) (Method 2), shotgun MS (HR)
837 (Method 3), and RP-UHPLC/MS (Method 4).

838

839 **Extended Data Fig. 6. Selected box plots for the Phase II.** Lipid concentrations normalized
840 with the NIST reference material determined in PDAC patients (443 T) and healthy controls
841 (95 N) including both validation and training sets and both genders: **a**, PC O-34:2, **b**, PC O-
842 34:3, **c**, PC O-36:4, **d**, Cer 36:1, **e**, Cer 42:1, **f**, Cer 42:2, **g**, SM 39:1, **h**, SM 40:1, **i**, SM 42:1,
843 **j**, LPC 16:0, **k**, LPC 20:4, and **l**, TG 52:6 for UHPSFC/MS (Method 1), shotgun MS (LR)
844 (Method 2), shotgun MS (HR) (Method 3), and RP-UHPLC/MS (Method 4).

845

846 **Extended Data Fig. 7. Results for the lipidomic profiling of female serum samples from**
847 **PDAC patients (T) and healthy controls (N) in the Phase III.** **a**, PCA for the training set
848 (211 T + 124 N). **b**, OPLS-DA for the training set (211 T + 124 N). Individual samples are
849 colored according to their tumor (T) stage: T1 - yellow, T2 - orange, T3 - red, T4 - rose, and
850 Tx - brown (no information about the stage was provided). **c**, Sensitivity (red), specificity
851 (blue), and accuracy (green) for the training and validation sets. **d**, S-plot for the training set
852 with the annotation of most up-regulated (red) and down-regulated (blue) lipid species. **e**,
853 Heat map for both training and validations sets (271 T + 134 N).

854




855 **Extended Data Fig. 8. Results for the lipidomic profiling of human serum samples for**
856 **PDAC patients (T) and healthy controls (N) including both genders in the Phase III. a,**
857 ROC curves for males (M) and females (F) in training (Tr.) and validation (Va.) sets. Box
858 plots of lipid molar concentrations normalized using the NIST reference material for: **b**, SM
859 41:1, and **c**, Cer 41:1. Only samples with known tumor (T) stage classification were included,
860 where early stages (T1 and T2, 24 males and 30 females) and late stages (T3 and T4, 174
861 males and 176 females) are summarized and compared to samples of healthy controls (128
862 males and 134 females) and pancreatitis patients (13 males and 9 females). Influence of
863 surgery on the lipidomic profile: **d**, OPLS-DA for females (211 T + 124 N) using the training
864 set with highlighted samples before (green, n=13) and after (orange, n=10) surgery. Box plots
865 of molar lipid concentrations for paired samples collected before and after surgery for both
866 genders (2 males and 10 females): **e**, SM 41:1, and **f**, LPC 18:2. Box plots for paired samples
867 collected before (n=22) and after treatment (n=22 for collection 1, n=12 for collection 2, n=7
868 for collection 3, n=4 for collection 4) for both genders using molar concentrations: **g**, SM
869 41:1, **h**, LPC 18:2, and **i**, Cer 41:1. OPLS-DA modes only for subjects before any treatment or
870 surgery separately for **j**, males (83 T + 122 N) and **k**, females (73 T + 124 N).

871

872 **Extended Data Fig. 9. Network visualization of the most dysregulated lipid species in**
873 **PDAC for data from Phase III.** Graphs show lipidomic pathways with clustering into
874 individual lipid classes for **a**, males, and **b**, females using the Cytoscape software
875 (<http://www.cytoscape.org>). Circles represent detected lipid species, where the circle size
876 expresses the significance according to p-value, while the color darkness defines the degree of
877 up-/down-regulation (red/blue) according to the fold change. The most discriminating lipids
878 are annotated.








879


880 **Extended Data Fig. 10. Potential of selected dysregulated lipid species for the survival**
881 **prognosis in the Phase II using Kaplan-Meier plots. a**, Gender (102 males and 98 females).
882 **b**, PC O-38:5 measured by UHPSFC/MS (n=98 for binary code 0, and n=102 for binary code
883 1). **c**, PC O-38:5 measured by shotgun MS (LR) (n=103 for 0, and n=97 for 1). **d**, PC O-38:5
884 measured by shotgun MS (HR) (n=103 for 0, and n=97 for 1). **e**, PC O-38:5 measured by RP-
885 UHPLC/MS (n=98 for 0, and n=102 for 1). **f**, PC 32:0 measured by shotgun MS (LR) (n=94
886 for 0, and n=106 for 1). **g**, PC 32:0 measured by shotgun MS (HR) (n=91 for 0, and n=109 for
887 1). **h**, PC 32:0 measured by RP-UHPLC/MS (n=90 for 0, and n=110 for 1). **i**, CA 19-9 (n=62
888 for 0, and n=138 for 1).





d


		Number	N	T	[%]	
M+F	N	79	73	6	92.4	Specificity
	T	213	6	207	97.2	Sensitivity
	All	292	6	6	95.9	Accuracy
M	N	30	30	0	100.0	Specificity
	T	104	2	102	98.1	Sensitivity
	All	134	2	0	98.5	Accuracy
F	N	49	49	0	100.0	Specificity
	T	109	2	107	98.2	Sensitivity
	All	158	2	0	98.7	Accuracy























a**b**